semaglutide blockage Wegovy class has higher GI side effect risk than older weight loss drug in study FDA Adds Intestinal Blockage as

It's less invasive, has a lower risk profile, and is fully supported by the bulk of the preclinical data demonstrating the peptide's systemic nature

Since insulin therapy often indicates more advanced disease progression, greater severity, or additional comorbidities, which may lead to a higher risk of intestinal obstruction, and there was no statistically significant difference in intestinal obstruction risk between GLP-1RAs and other anti-diabetic medications (e.g., SGLT2 inhibitors, metformin, sulfonylureas, thiazolidinediones, DPP-4 inhibitors), the observed reduction relative to insulin does not necessarily suggest a protective effect of GLP-1RAs against intestinal obstruction

Vniant, M

Brain 140 , 21122119 (2017)